• Element Materials Technology agreed to buy pharmaceutical analytical testing company Avomeen to expand its North American life sciences business.
• Avomeen, based in Ann Arbor, Michigan, focuses on pharmaceutical testing, biotechnology, and FDA-regulated consumer products.
• The deal adds an 80-person scientific team, including about 20% PhDs, strengthening capabilities in formulation chemistry and large-molecule testing.
• Avomeen posted 23% revenue growth in 2020, as it supported Covid-19 diagnostics, therapies, and hand sanitizer manufacturers.
• Element said life sciences now accounts for nearly 20% of group revenue, following acquisitions including ALG in 2020.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Element Ventures published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.